Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.
| Website: | www.transitiontherapeutics.com |
| Email: | info@transitiontherapeutics.com |
| Main Phone: | +1 416 260-7770 |
| Address: | 101 College Street |
| Address 2: | Suite 220 |
| State: | ON |
| City / Town: | Toronto |
| Country: | CAN |
| Postal Code: | M5G 1L7 |
| Exchange: | TSX |
| CEO: | Tony F. Cruz |
| Employees: | 18 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.
| Website: | www.transitiontherapeutics.com |
| Email: | info@transitiontherapeutics.com |
| Main Phone: | +1 416 260-7770 |
| Address: | 101 College Street |
| Address 2: | Suite 220 |
| State: | ON |
| City / Town: | Toronto |
| Country: | CAN |
| Postal Code: | M5G 1L7 |
| Exchange: | TSX |
| CEO: | Tony F. Cruz |
| Employees: | 18 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume 0 | 52 Wk Hi 3.54 | 52 Wk Low 0.89 |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 38,798,971.00 | EPS (TTM) -0.65 | PE Ratio N/A | Exchange TSX |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 5.5 | 5.5 | 5.5 | 5.5 |
| Low Target Price Estimate | 5.5 | 5.5 | 5.5 | 5.5 |
| Mean Target Price Estimate | 5.5 | 5.5 | 5.5 | 5.5 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 04/29/14 | 04/29/14 | 04/29/14 | 04/29/14 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 3 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
